Business
To GLP or not to GLP? That is the question... knowing the answer and choosing the right CRO may save you time and money
Good Laboratory Practices (GLP) are federal regulations that require implementation of a robust quality management system to ensure the validity, integrity and reliability of non-clinical safety data submitted for regulatory evaluation and approval. US Food and Drug Administration (FDA) GLP regulations (21 CFR parts 11 and part 58) were first issued by the US in 19781, and, at that time, safety data was mainly obtained from in vivo animal test systems.
S
ince then, researchers have continued to develop alternative ways to assess drug safety, and now, GLP regulations can be applied to
all non-clinical laboratory safety studies, including in vitro and ex vivo test systems. In short, GLP-compliant studies require docu-
mentation (eg standard operating procedures) and are overseen by quality assurance units that per- form process-, facility- and study-based inspec- tions. In this article, we provide an overview of which studies require GLP compliance, which do not, and why in some cases the choice is unclear. Understanding the details of your prospective
contract research organisation’s (CRO) GLP-com- pliant and non-GLP compliant study conduct is key. Once you know exactly what to expect, you can select the level of study you need to achieve your project’s objectives – and possibly, depending upon the CRO, save time and funds by choosing non-GLP.
Which studies require GLP? With formal regulations in place, you’d think the answer to this question would be simple. It is, and
Drug Discovery World Winter 2018/19
it isn’t. In summary, the FDA guidelines for GLP compliance are as follows:
1. Evidence that their products are safe in research and/or marketing applications (21 CFR 58.1) must be submitted by sponsors of non- clinical laboratory studies to support the safety of: l Food and colour additives l Animal food additives l Animal drugs l Human drugs and biological products l Medical devices for human use l Electronic products
2. Non-clinical laboratory studies that must comply with FDA GLP regulations include: l Toxicity profiles l Observed no adverse effect levels l Risks of clinical studies involving humans or animals l Potential teratogenic, carcinogenic or other adverse effects l Safe levels of use
61
By Scott Hickman, Dr Brian Ogilvie and Tim Patterson
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68
